Methods and compositions for diagnosis and prognosis of sepsis

Patent metadata

Field	Value
Publication number	US-2016282344-A1
Application number	US-201415036805-A
Country	US
Kind code	A1
Filing date	Nov 15, 2014
Priority date	Nov 15, 2013
Publication date	Sep 29, 2016
Grant date	—

Abstract

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in sepsis patients and in patients at risk for sepsis. In particular, the invention relates to using assays that detect one or more biomarkers as diagnostic and prognostic biomarker assays in such patients.

First claim

1 . A method of diagnosing SIRS, sepsis, severe sepsis, septic shock, or MODS in a subject, or assigning a prognostic risk for one or more clinical outcomes for a subject suffering from SIRS, sepsis, severe sepsis, septic shock, or MODS, the method comprising:
performing one or more assays configured to detect one or more biomarkers selected from the group consisting of Extracellular matrix protein 1, Coagulation factor XIII B chain, Vitronectin, Stanniocalcin-1, Annexin A2, Syndecan-1, and Antithrombin-III on a body fluid sample obtained from the sepsis patient to provide one or more assay result(s); and relating the assay result(s) to one or more diagnoses or prognoses selected from the group consisting of the presence or absence of SIRS, the presence or absence of sepsis, the presence or absence of severe sepsis, the presence or absence of septic shock, the presence or absence of MODS, and the prognostic risk of one or more clinical outcomes for the subject suffering from or believed to suffer from SIRS, sepsis, severe sepsis, septic shock, or MODS.

2 . A method according to claim 1 , wherein the relating step comprises relating the immunoassay result to a prognostic risk of mortality.

3 . A method according to claim 1 , wherein the relating step comprises relating the immunoassay result to a prognostic risk of one or more future changes in renal status.

4 . A method according to claim 3 , wherein said one or more future changes in renal status comprise one or more of a future injury to renal function, future reduced renal function, future improvement in renal function, and future acute renal failure (ARF).

5 . A method according to claim 1 , wherein said relating step comprises comparing each of the immunoassay result(s) to a corresponding predetermined threshold level selected to provide a sensitivity or specificity of at least 0.7 for the diagnosis of sepsis, compared to SIRS not progressed to sepsis.

6 . A method according to claim 1 , wherein said relating step comprises comparing each of the assay result(s) to a corresponding predetermined threshold level selected to provide a sensitivity or specificity of at least 0.7 for the diagnosis of severe sepsis, compared to SIRS not progressed to severe sepsis.

7 . A method according to claim 1 , wherein said relating step comprises comparing each of the assay result(s) to a corresponding predetermined threshold level selected to provide a sensitivity or specificity of at least 0.7 for the diagnosis of septic shock, compared to SIRS not progressed to septic shock.

8 . A method according to claim 1 , wherein said relating step comprises comparing each of the assay result(s) to a corresponding predetermined threshold level selected to provide an odds ratio of at least 2 for the prognostic risk of mortality.

9 . A method according to claim 1 , wherein said relating step comprises comparing each of the assay result(s) to a corresponding predetermined threshold level selected to provide an odds ratio of at least 2 for the prognostic risk of a worsening sepsis classification level selected from the group consisting of severe sepsis, septic shock, and MODS.

10 . A method according to claim 1 , wherein said relating step comprises comparing each of the assay result(s) to a corresponding predetermined threshold level selected to provide an odds ratio of at least 2 for the prognostic risk of one or more of a future injury to renal function, future reduced renal function, future improvement in renal function, and future ARF.

11 . A method according to claim 1 , wherein the sample is selected from the group consisting of blood, serum, and plasma.

12 . A method according to claim 1 , wherein the method is a prognostic method, and the method differentiates between a risk of future sepsis and a risk of future severe sepsis or septic shock.

13 . A method according to claim 1 , wherein the method is a prognostic method, and the method differentiates between a risk of future sepsis or severe sepsis and a risk of future septic shock.

14 . A method according to claim 1 , wherein the method is a diagnostic method, and the method differentiates between a diagnosis of sepsis and a diagnosis of severe sepsis or septic shock.

15 . A method according to claim 1 , wherein the method is a diagnostic method, and the method differentiates between a diagnosis of sepsis or severe sepsis and a diagnosis of septic shock.

16 . A method according to claim 1 , wherein the one or more assays are one or more immunoassays.

17 . A method according to claim 16 , wherein each of the one or more immunoassays is performed by introducing the body fluid sample obtained from the subject into an assay instrument which contacts all or a portion of the urine sample with a binding reagent which specifically binds for detection the biomarker being assayed and generates an assay result indicative of binding of the biomarker being assayed to the binding reagent.

18 . A method according to claim 1 , wherein a plurality of assay results are combined using to provide a combined assay result which is a single composite value that is a function of the plurality of assay results, and the relating step comprises relating the combined assay result to the one or more diagnoses or prognoses.

19 . A method according to claim 1 , wherein the subject is treated for sepsis if the relating step indicates the presence of sepsis, the presence of severe sepsis, the presence of septic shock, the presence of MODS, or if the relating step indicates a substantial prognostic risk of one or more clinical outcomes for the subject suffering from or believed to suffer from SIRS, sepsis, severe sepsis, septic shock, or MODS.

20 - 29 . (canceled)

Assignees

• Astute Medical Inc
• Univ Of Pittsburgh - Of The Commonwealth System Of Higher Education

Inventors

• Anderberg Joseph
• Gray Jeff
• Mcpherson Paul
• Nakamura Kevin
• Kampf James Patrick
• Kwan Thomas
• Kellum John A
• Angus Derek C

Classifications

• G01N2333/4724

  Lectins · CPC title

• G01N2333/47

  Assays involving proteins of known structure or function as defined in the subgroups · CPC title

• G01N33/56911 Primary

  Bacteria · CPC title

• G01N2800/26

  Infectious diseases, e.g. generalised sepsis · CPC title

• G01N2800/52

  Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis · CPC title